PwC views Russia's new federal law 'On the Circulation of Pharmaceuticals

The Russian pharmaceutical market has undergone significant changes in the past couple of years, and these changes are set to continue with the introduction of new Federal Law No. 61-FZ of April 12, 2010, On the Circulation of Pharmaceuticals, notes Aina Lavrentieva, partner, pharmaceutical practice leader at PricewaterhouseCoopers, in that country, quoted by the Moscow Times. The Law is aimed at improving legislation regulating the circulation of pharmaceuticals, taking into account the development priorities for the pharmaceutical industry in Russia.

Despite the efforts of the Russian Federal Anti-Monopoly Service, the Law does not contain provisions developed by this agency aimed at restricting the promotion of pharmaceuticals by pharmaceutical companies through medical representatives. Further, despite foreign pharmaceutical manufacturers' expectations, the Law also does not establish any special regulations for the importers of pharmaceuticals that are the subsidiaries of foreign companies.

Most important provisions of the Law